Open AccessS175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM‐CELL TRANSPLANT FOR MULTIPLE MYELOMA
Author(s) -
Dytfeld D.,
Wróbel T.,
Jamroziak K.,
Kubicki T.,
Robak P.,
WalterCroneck A.,
Czyż J.,
Tyczyńska A.,
DruzdSitek A.,
Giannopoulos K.,
Nowicki A.,
Szczepaniak T.,
ŁojkoDankowska A.,
Matuszak M.,
Gil L.,
Puła B.,
Rybka J.,
Majcherek M.,
UsnarskaZubkiewicz L.,
Szukalski L.,
Końska A.,
Zaucha J. M.,
Walewski J.,
Mikulski D.,
Czabak O.,
Robak T.,
Grzybowska U.,
Lahoud O. B.,
Zonder J. A.,
Griffith K.,
Stefka A.,
Major A.,
Derman B. A.,
Jakubowiak A. J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843592.63620.b4
Subject(s) - lenalidomide , carfilzomib , medicine , multiple myeloma , dexamethasone , autologous stem cell transplantation , clinical endpoint , randomized controlled trial , oncology , surgery